Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival

被引:67
|
作者
Changchien, Chi-Sin [1 ]
Chen, Chao-Long
Yen, Yi-Hao [1 ]
Wang, Jing-Houng [1 ]
Hu, Tsung-Hui [1 ]
Lee, Chuan-Mo [1 ]
Wang, Chih-Chi
Cheng, Yu-Fan [2 ]
Huang, Yu-Jie [3 ]
Lin, Chih-Yun [1 ]
Lu, Sheng-Nan [1 ,4 ]
机构
[1] Chang Gung Univ Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med,Div Hepatogastroenterol, Kaohsiung 833, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp,Dept Radiol, Kaohsiung, Taiwan
[3] Chang Gung Univ, Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp,Dept Radiat Oncol, Kaohsiung, Taiwan
[4] Xiamen Chang Gung Hosp, Xiamen, Peoples R China
关键词
hepatocellular carcinoma; survival; prognostic factors; hepatitis B virus;
D O I
10.1007/s00535-007-2134-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background This hospital-based analysis was conducted to identify prognostic factors of hepatocellular carcinoma (HCC) in a hepatitis B virus endemic area. Methods. A total of 6381 HCC cases, diagnosed from 1986 to 2002, were enrolled, and 2890 (42.3%) of them were not treated. Survival rates were analyzed by correlation with the national mortality databank. Missing data and correlations among prognostic factors were considered in the analysis. Results. The overall 1-year, 3-year, 5-year, and 7-year survival rates were 44.3%, 24.9%,1.7.1%,and 13%, respectively. Multivariate analysis revealed that the independent factors influencing survival were the initial treatment modality, degree of liver function impairment, hepatitis B surface antigen positivity, tumor status, and (x-fetoprotein. Besides these well-known prognostic factors, high alanine aminotransferase (ALT) levels and a high aspartate aminotransferase (AST)/ALT ratio were identified as independent poor prognostic factors. Conclusions. This study, which considered untreated cases, missing data, and correlations between variables and official survival data sets, provides a large-scale comprehensive survival analysis. According to our results, high ALT and high AST/ALT were independent poor prognostic factors. Therefore, viral activity should be controlled in HCC patients, and patients with elevated AST/ALT ratios should be carefully monitored.
引用
收藏
页码:159 / 170
页数:12
相关论文
共 50 条
  • [41] Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization
    Sanchez-Delgado, Jordi
    Vergara, Mercedes
    Machlab, Salvador
    Lira, Alba
    Gomez Zaragoza, Carlos
    Criado, Eva
    Rosinach, Merce
    Batista, Lissette
    Arau, Beatriz
    Roget, Merce
    Ortiz, Jordi
    Garcia, Caridad
    Sort, Pau
    Casas, Meritxell
    Dalmau, Blai
    Forne, Montserrat
    Falco, Joan
    Miquel, Mireia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (12) : 1453 - 1460
  • [42] Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma
    Pisit Tangkijvanich
    Varocha Mahachai
    Pongspeera Suwangool
    Yong Poovorawan
    World Journal of Gastroenterology, 2004, (11) : 1547 - 1550
  • [43] Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma
    Tangkijvanich, Pisit
    Mahachai, Varocha
    Suwangool, Pongspeera
    Poovorawan, Yong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (11) : 1547 - 1550
  • [44] Pathologic features and patients survival in hepatocellular carcinoma in relation to age
    Trotovsek, B
    Gadzijev, EM
    EUROPEAN CONGRESS I.H.P.B.A. "BUDAPEST 1999", 1999, : 281 - 284
  • [45] Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors
    Liu, Zi-Yi
    Kan, Xue-Feng
    Zhang, Li-Jie
    Makamure, Joyman
    Li, Qing
    Zhao, Dan
    Zhou, Guo-Feng
    Feng, Gan-Sheng
    Zheng, Chuan-Sheng
    Liang, Bin
    CURRENT MEDICAL SCIENCE, 2022, 42 (05) : 1015 - 1021
  • [46] Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors
    Zi-yi Liu
    Xue-feng Kan
    Li-jie Zhang
    Joyman Makamure
    Qing Li
    Dan Zhao
    Guo-feng Zhou
    Gan-sheng Feng
    Chuan-sheng Zheng
    Bin Liang
    Current Medical Science, 2022, 42 : 1015 - 1021
  • [47] Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma
    Kaseb, Ahmed O.
    Shama, Mohamed
    Sahin, Ibrahim Halil
    Nooka, Ajay
    Hassabo, Hesham M.
    Vauthey, Jean-Nicolas
    Aloia, Thomas
    Abbruzzese, James L.
    Subbiah, Ishwaria M.
    Janku, Filip
    Curley, Steven
    Hassan, Manal M.
    ONCOLOGY, 2013, 85 (04) : 197 - 203
  • [48] Glasgow Prognostic Score and modified Glasgow Prognostic Score and survival in patients with hepatocellular carcinoma: a meta-analysis
    Lu, Lingling
    Lin, Kunzhe
    Zheng, Jiaolong
    Wu, Haicong
    Li, Dongliang
    BMJ OPEN, 2021, 11 (12):
  • [49] Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation
    Kang Wang
    Yan-Jun Xiang
    Hong-Ming Yu
    Yu-Qiang Cheng
    Jin-Kai Feng
    Zong-Han Liu
    Yun-Feng Shan
    Yi-Tao Zheng
    Qian-Zhi Ni
    Shu-Qun Cheng
    BMC Cancer, 23 (1)
  • [50] Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation
    Wang, Kang
    Xiang, Yan-Jun
    Yu, Hong-Ming
    Cheng, Yu-Qiang
    Feng, Jin-Kai
    Liu, Zong-Han
    Shan, Yun-Feng
    Zheng, Yi-Tao
    Ni, Qian-Zhi
    Cheng, Shu-Qun
    BMC CANCER, 2023, 23 (01)